Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Trends in Cancer
|
September 25, 2020
Harnessing Real-World Evidence for the Development of Novel Cancer Therapies
Joel Greshock, Martine Lewi, Bert Hartog, et al.
The American Journal of Bioethics : AJOB
|
September 22, 2023
Academic and Private Partnership to Improve Informed Consent Forms Using a Data Driven Approach
Craig Tendler, Patricia S Hong, Conor Kane, et al.
Cancer
|
July 19, 2002
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation
Ronald M Bukowski, Craig Tendler, David Cutler, et al.
British Journal of Haematology
|
September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data
Deanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2023
Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges
Lola A Fashoyin-Aje, Craig Tendler, Bea Lavery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
Alan M Keller, Robert G Mennel, Vassilis A Georgoulias, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
Fadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
Transplantation and Cellular Therapy
|
February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles
Kedar Kirtane, Michael Kalos, Rocky Billups, et al.
Blood Advances
|
August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Sheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Nature Medicine
|
April 20, 2022
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
Bob T Li, Bobby Daly, Mary Gospodarowicz, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Trends in Cancer
|
September 25, 2020
Harnessing Real-World Evidence for the Development of Novel Cancer Therapies
Joel Greshock, Martine Lewi, Bert Hartog, et al.
The American Journal of Bioethics : AJOB
|
September 22, 2023
Academic and Private Partnership to Improve Informed Consent Forms Using a Data Driven Approach
Craig Tendler, Patricia S Hong, Conor Kane, et al.
Cancer
|
July 19, 2002
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation
Ronald M Bukowski, Craig Tendler, David Cutler, et al.
British Journal of Haematology
|
September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data
Deanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2023
Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges
Lola A Fashoyin-Aje, Craig Tendler, Bea Lavery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2004
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
Alan M Keller, Robert G Mennel, Vassilis A Georgoulias, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
Fadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
Transplantation and Cellular Therapy
|
February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles
Kedar Kirtane, Michael Kalos, Rocky Billups, et al.
Blood Advances
|
August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Sheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Nature Medicine
|
April 20, 2022
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
Bob T Li, Bobby Daly, Mary Gospodarowicz, et al.
Page
of 2